GSK plc (LON:GSK) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of GSK plc (LON:GSK) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is GBX 1,842.50 ($23.47).

A number of equities analysts have recently weighed in on the stock. Shore Capital reissued a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 1,850 ($23.56) price objective on shares of GSK in a research note on Tuesday, September 3rd. Finally, Berenberg Bank reissued a “buy” rating and issued a GBX 1,820 ($23.18) target price on shares of GSK in a research note on Tuesday, September 10th.

GSK Stock Performance

Shares of LON:GSK opened at GBX 1,336.33 ($17.02) on Monday. The company has a market capitalization of £54.52 billion, a price-to-earnings ratio of 1,182.59, a P/E/G ratio of 1.24 and a beta of 0.31. The firm’s 50 day simple moving average is GBX 1,437.76 and its 200 day simple moving average is GBX 1,552.20. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. GSK has a fifty-two week low of GBX 1,282.50 ($16.34) and a fifty-two week high of GBX 1,823.50 ($23.23).

GSK Dividend Announcement

The company also recently declared a dividend, which will be paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th will be paid a GBX 15 ($0.19) dividend. This represents a dividend yield of 1.03%. The ex-dividend date is Thursday, November 14th. GSK’s dividend payout ratio is 5,309.73%.

Insider Transactions at GSK

In other GSK news, insider Elizabeth (Liz) McKee Anderson purchased 446 shares of the business’s stock in a transaction on Monday, September 23rd. The shares were purchased at an average cost of GBX 2,051 ($26.12) per share, with a total value of £9,147.46 ($11,651.33). Also, insider Jonathan Symonds acquired 7,150 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of GBX 1,394 ($17.76) per share, with a total value of £99,671 ($126,953.25). Insiders bought 7,604 shares of company stock valued at $10,893,038 over the last three months. Company insiders own 1.61% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.